New study matches melanoma patients to drugs based on their Tumor's genes

NCT ID NCT02645149

Completed Disease control Sponsor: Melanoma Institute Australia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 216 people with advanced melanoma that had stopped responding to standard treatments. Researchers tested each person's tumor for specific genetic changes and then gave them a drug designed to target that change. The goal was to see if this personalized approach could shrink tumors or slow the cancer's growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Targeted drugs (e.g., trametinib, ceritinib, ribociclib, pazopanib) matched to specific genetic mutations in the tumor
What this could lead to: If successful, this approach could offer a new treatment option for people with advanced melanoma whose cancer has stopped responding to standard immunotherapy.
What could go wrong: This is a Phase 2 trial with a small number of participants, so results may not apply to everyone. The targeted drugs may not work for all mutations, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Melanoma Institute Australia

Wollstonecraft, New South Wales, 2260, Australia
Westmead Hospital

Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.